Overview of Alahist CF

What is Alahist CF? Defining the Triple-Action Combination

Property	Description
Active ingredient	Dexbrompheniramine, Dextromethorphan, Phenylephrine
Form	Oral tablet or Oral liquid solution
Pharmacological class	Combination Antihistamine, Antitussive, Decongestant
Common use	Symptomatic relief of upper respiratory conditions
Origin	Synthetic organic compounds

Alahist CF is a fixed-ratio triple-component pharmaceutical preparation intended for Oral administration. It is supplied as an Oral tablet or Oral liquid solution and is formally identified as a Combination product because it utilizes three distinct synthetic organic compounds to address multiple symptom pathways concurrently. This type of combination medication is generally employed for treating multiple cold and allergy symptoms, helping to stabilize overall physical discomfort.

This formulation is clinically recognized for its ability to target the diverse and overlapping symptoms characteristic of Upper Respiratory Allergies and the Common Cold symptoms. Unlike single-agent products, the triple combination design is distinct, providing both relief from congestion and control over cough and allergic responses in one unit, which streamlines symptomatic management for the General use population.

Composition and Coordinated Therapeutic Benefit

The identity of Alahist CF is established by its three Active ingredients: Dexbrompheniramine maleate, Dextromethorphan hydrobromide, and Phenylephrine hydrochloride. These ingredients determine its classification as a Combination Antihistamine, Antitussive, and Decongestant.

Each component belongs to a unique Pharmacological class and serves a specific function. Dexbrompheniramine is an H1 Antagonist that provides relief through Histamine blocking. Dextromethorphan is the Antitussive component, which acts to provide Cough suppression. The final component, Phenylephrine, is classified as an Alpha-1 Adrenergic Receptor Agonist that functions as a decongestant primarily through local Vasoconstriction in the nasal passages. The Coordinated Therapeutic Benefit of this combination is designed to manage the common cycle of irritation, post-nasal drip, and congestion.

Regulatory References

DailyMed Label for Alahist CF

What side effects are possible with Alahist CF?

Possible Side Effects and Safety Information

The safety profile of Alahist CF, a triple-component medication containing a decongestant, an antihistamine, and an antitussive, is characterized by potential effects across several body systems as documented in official regulatory labeling.

Adverse Reaction Scope

Classification Aspect	Officially Documented Regulatory Information
System-Organ Classes	Effects on the Nervous System (e.g., drowsiness, dizziness, nervousness), Cardiovascular System (e.g., changes in heart rate, increased blood pressure), Gastrointestinal System (e.g., dry mouth, constipation), and Ophthalmic System (e.g., blurred vision) are documented.
Common Reactions	Expected common reactions include drowsiness or marked drowsiness, dry mouth/nose/throat, nausea, sleeplessness, and nervousness.
Serious Reactions	Serious adverse reactions explicitly listed in regulatory documents include seizure, significant hypertension, fast or irregular heartbeats, and signs of a severe allergic reaction such as swelling or difficulty breathing.

Regulatory Safety Considerations

The medicine carries specific safety constraints defined by regulatory authorities. Use is strictly forbidden if the individual is currently taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of stopping one, due to the potential risk of a life-threatening hypertensive crisis.

Population-Specific Notes indicate that older adults may be more susceptible to side effects like confusion and dizziness. For children, a paradoxical reaction of excitability may occur instead of drowsiness. Furthermore, caution is advised for individuals with pre-existing conditions such as high blood pressure, heart disease, or glaucoma, as the product may affect these conditions.

Overdose and Emergency Response

The official regulatory documentation on overdose for Alahist CF establishes a risk profile centered on severe toxicity affecting the Central Nervous System (CNS) and the cardiovascular system. Documented clinical manifestations of overdose may begin with agitation, confusion, and hallucinations, often accompanied by anticholinergic signs like dilated pupils or trouble urinating. These effects can rapidly escalate to profound CNS depression, leading to seizures or coma. Severe, life-threatening presentations involve slow or shallow breathing (respiratory compromise) and significant cardiac instability, including a fast, irregular heartbeat and high blood pressure.

The regulatory profile mandates that immediate emergency medical attention must be sought for any suspected overdose. Individuals are explicitly required to contact a Poison Control Center right away and call emergency services if acute symptoms such as loss of consciousness, seizures, or difficulty breathing are observed.

Management is restricted to symptomatic and supportive treatment, with continuous cardiac monitoring noted as an essential requirement. Official labeling indicates increased risk in specific groups: children may experience unique symptoms where initial excitement precedes severe CNS depression, and the elderly may demonstrate heightened sensitivity to both CNS and cardiovascular effects.

Therapeutic Uses of Alahist CF

What Alahist CF Treats: Main Uses and Benefits

This medication is applied across domains where short-term symptomatic assistance is needed, primarily to temporarily relieve the distress associated with the common cold, hay fever, and other upper respiratory allergies. It helps address symptom clusters that may become intense or disruptive, such as a runny nose, sneezing, itchy/watery eyes, nasal congestion, and cough. It is utilized for managing groups of symptoms that often occur together during acute episodes.

Symptom Focus: Nasal Congestion and Irritation

The medication is helpful in situations where multiple symptoms occur together and provides support that helps ease the overall symptom burden during periods of heightened discomfort. It is often used when symptoms intensify and supportive relief is needed, and is relevant for easing symptoms that create noticeable functional strain. This symptomatic relief may assist with maintaining functional stability and supports general well-being during symptomatic phases. It helps to ease distress and may help patients cope more steadily with symptom fluctuations.

Regulatory References

DailyMed (NIH) Drug Label Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Alahist CF?

This medication's eligibility profile is defined by official regulatory criteria that specify absolute prohibitions, conditional use, and age limits.

Populations for Whom Use is Contraindicated

Use of Alahist CF is absolutely contraindicated (must not be used) in patients who are currently taking a Monoamine Oxidase Inhibitor (MAOI), or who have discontinued an MAOI prescription drug within the last 14 days. Use is also prohibited in individuals with known hypersensitivity or allergy to dexbrompheniramine, dextromethorphan, phenylephrine, or any components of the formulation.

Age-Related Eligibility Rules

Age Group	Regulatory Status
Adults (≥ 18) and Adolescents (≥ 12)	Approved for use
Children 6 to under 12 years	Use established with a specific reduced dosage
Children under 6 years	Use not established for cold symptoms; consult a health professional

Conditional Use and Restrictions

Official labeling requires individuals with certain chronic conditions to ask a health professional before use. These conditions include heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or trouble urinating due to an enlarged prostate gland. Conditional use also applies to pregnant or breastfeeding individuals.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific drug and substance interactions for Alahist CF, structuring the product's use around mandatory prohibitions and risks of additive effects.

Interaction Constraints and Prohibitions

The co-administration of Alahist CF with Monoamine Oxidase Inhibitors (MAOIs), including Isocarboxazid and Phenelzine, is formally contraindicated. The regulatory label mandates a 14-day separation period; Alahist CF must not be used for two weeks after stopping an MAOI drug. Combination with other Ergot Alkaloids is also prohibited due to the risk of severe sympathomimetic effects.

Additive Pharmacodynamic Effects

Co-use with other Central Nervous System (CNS) Depressants, such as alcohol (ethanol), sedatives, or opioid pain relievers, results in additive CNS depression (e.g., increased drowsiness). Combining the product with other Sympathomimetic Agents or CNS stimulants increases the risk of potentiation of cardiovascular effects, including hypertension. The Phenylephrine component may also interfere with the glucose-lowering effects of Antidiabetic Medications.

Pharmacokinetic and Substance Interactions

Drugs that inhibit the CYP2D6 enzyme may cause increased Dextromethorphan exposure and subsequently exaggerate its effects. The label also notes that Grapefruit Juice may increase the bioavailability of Dextromethorphan. Interactions are further classified for the Elderly Population and CYP2D6 Poor Metabolizers who may experience a greater magnitude of documented interaction effects.

Mechanism of Action

How Alahist CF Works

Alahist CF exerts its action through a three-pronged pharmacodynamic mechanism targeting distinct signaling pathways. Dexbrompheniramine acts as a competitive antagonist at the histamine H1 receptors, interrupting the signaling cascade that increases capillary permeability and stimulates sensory nerves. This action results in the physiological outcome of diminished plasma leakage and reduced excitability of peripheral sensory endings.

Phenylephrine functions as an agonist on the alpha1-adrenergic receptors located on vascular smooth muscle in the respiratory mucosa. This interaction engages the sympathetic pathway to induce vasoconstriction, a process that limits local blood flow and fluid transudation. The consequence is the adjustment of mucosal volume and increased airway lumen diameter.

Dextromethorphan modulates the central nervous system by acting as an N-methyl-D-aspartate (NMDA) receptor antagonist in the medullary cough center. This central action elevates the threshold of neuronal activity required for afferent stimuli to initiate the efferent phase of the somatic cough reflex arc.

Dosage and Administration Information

How to Use Alahist CF

The administration of Alahist CF is governed by the fixed-dose combination and is defined by guidelines focusing on the route, frequency, and maximum allowable dose.

Official Administration Protocol

The medication is designed for oral administration only and is available in both tablet and liquid solution dosage forms. The use pattern is intermittent and based on a fixed time interval.

Age Group	Single Dose Unit	Maximum Daily Frequency (24 hours)
Adults and Children ge 12 years	1 tablet or 1 unit-dose liquid	6 doses
Children 6 to under 12 years	1/2 tablet or 1/2 unit-dose liquid	3 doses

Frequency and Contextual Use

To manage symptoms, the dose unit is typically repeated every 4 to 6 hours. This regimen must not be exceeded, as labeling defines the maximum daily amount. The medication may be taken with or without food.

Alahist CF is intended for temporary relief only. Continuous use is generally constrained to a short duration, such as 7 days, unless otherwise directed. If a dose is missed, instructions advise skipping the missed dose and resuming the regular schedule; the dose should not be doubled. The administration of liquid formulations requires the use of a calibrated dosing device to ensure precision. Use in children under 6 years of age requires prior consultation with a healthcare provider.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alahist CF

The clinical evaluation of Alahist CF, a combination product containing an antihistamine, an antitussive, and a decongestant, was observed in various research efforts. The evidence base often involves data from both the combination itself and the established pharmacological classes of its individual components. Research examined two primary areas compatible with its stated uses: the common cold and upper respiratory allergies, which are explored below.

Evidence for Temporary Relief of Acute Common Cold Symptoms

Research explored the use of this combination in studies involving participants experiencing acute common cold symptoms. Researchers used short-term Randomized Controlled Trials (RCTs) to assess its application in adult and older child populations. These studies examined patient-reported outcomes describing perceived discomfort, such as changes in total symptom scores, and measures of cough frequency and nasal symptoms. Evidence for the antitussive and antihistamine components contributes to the broader evidence landscape regarding symptoms in this context.

However, data for certain groups remain insufficient, and the follow-up durations were limited. A key area of scientific uncertainty relates to the decongestant component, oral phenylephrine. The available research exploring its effectiveness in reducing nasal congestion, particularly at the recommended doses, appears to be limited or inconsistent. This evidence gap is linked to the uncertainty regarding the full triple combination's data related to congestion relief.

Evidence for Managing Upper Respiratory Allergies

The combination was evaluated in research exploring short-term symptom changes in conditions characterized by fluctuating or episodic manifestations, such as seasonal allergic rhinitis (hay fever). Study designs involved RCTs and systematic reviews primarily focused on the antihistamine component. The research examined outcomes linked to inflammatory or irritative states, specifically targeting symptoms like sneezing, runny nose, nasal itching, and watery eyes.

Despite the body of research describing the antihistamine component, certainty remains low regarding the research findings related to the combination's effect due to concerns over the oral decongestant component. Furthermore, research was associated with the observation that certain effects, such as sedation, was observed in some studies to correlate with changes in functional outcomes.

The Study Landscape: Key Limitations and Research Gaps

Overall, the existing evidence describes the scope of what has been studied and what remains uncertain about this combination product. A major limitation across both indications is the uncertainty surrounding the oral Phenylephrine component's effectiveness as a nasal decongestant at the doses studied. Additionally, the research focusing on the combination is characterized by follow-up durations were limited. Because the product is a fixed-ratio combination, comparative evidence is lacking that clearly isolates the contribution of each of the three components when taken together. Study results reflect the specific conditions under which they were conducted and research does not determine whether an individual will respond similarly.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Alahist CF (FAQ)

Q: Is Alahist CF a type of antihistamine?

A: Yes, Alahist CF is described in official regulatory documents as a combination product that contains three types of active ingredients. One of these active ingredients, Dexbrompheniramine, is classified as an antihistamine.

Q: Is Alahist CF similar to common over-the-counter cold medicines?

A: Alahist CF is identified as a fixed-ratio triple combination product, which means it contains an antihistamine, a cough suppressant, and a decongestant. This specific combination of components helps distinguish its pharmacological profile from products containing only one or two active ingredients.

Q: Are there any common foods or drinks that interact with Alahist CF?

A: Official regulatory labeling explicitly advises against using this product with alcohol. Furthermore, one component's interaction is noted to be affected by Grapefruit Juice. It is important to review the official product information for a full list of known substance interactions.

Q: Can Alahist CF be used for allergies or just for cold symptoms?

A: According to the official product information, Alahist CF is indicated for the temporary relief of symptoms caused by both the common cold and upper respiratory allergies, such as hay fever.

Q: What patient groups are generally advised against using Alahist CF?

A: Use is strictly contraindicated (must not be used) in patients currently taking or who have recently stopped using a Monoamine Oxidase Inhibitor (MAOI). Individuals with certain pre-existing conditions, such as high blood pressure, heart disease, diabetes, or glaucoma, are required by regulatory guidance to involve consultation with a health professional before use.

Q: Is Alahist CF the same drug as a different brand name I have heard of?

A: Alahist CF is a specific combination of three active ingredients. Regulatory practice allows for the same combination of drug components to be available under different brand names, depending on the manufacturer or location.

Q: What information is usually found on the official drug label for Alahist CF?

A: The official regulatory label, often called the Drug Facts Panel, is required to contain key information. These sections typically include the active ingredients, the intended purposes (uses) of the drug, important warnings (such as contraindications and side effects), and directions for use.

Q: What is the recommended period of use for Alahist CF?

A: The official product directions specify that this medication is intended for temporary relief only. The regulatory label advises that it should be used for a short duration, generally not to exceed 7 days, unless directed otherwise by a health professional.

Q: Is Alahist CF used for symptoms related to the flu?

A: Official regulatory information lists the product's uses for the temporary relief of symptoms caused by the common cold, allergies, or the flu. It is indicated for the overlapping symptoms that occur with these types of respiratory conditions.

Q: How quickly can I expect Alahist CF to start working?

A: Based on regulatory information regarding the active ingredients, the combination product is typically reported to begin having an effect within 30 minutes to one hour after it is taken orally. The reported onset time is based on general population data.

Q: How long does the effect of Alahist CF typically last?

A: The therapeutic effect of the combination product generally lasts for approximately 4 to 6 hours. This duration aligns with the typical recommended dosing interval stated in the product directions.

Q: Is it normal to feel a little dizzy after taking Alahist CF?

A: Dizziness is explicitly documented as a potential adverse reaction in the official regulatory labeling for this product. It is one of the effects noted in the safety information.

Q: Is Alahist CF known to interact with caffeine?

A: The Phenylephrine component is a sympathomimetic agent (a type of stimulant). Regulatory warnings advise that using the product with other stimulants, including caffeine, can lead to additive cardiovascular effects, such as an increase in blood pressure or heart rate.

Q: Is Alahist CF generally considered safe for long-term use?

A: Official directions specify that this is for short-term use and should not be used for a period longer than directed (e.g., typically limited to 7 days). Long-term use without consulting a health professional is not advised in the regulatory information.

Q: Why is Alahist CF sometimes prescribed for non-cold symptoms?

A: The product is officially indicated for the relief of symptoms due to the common cold, but regulatory documents also list its use for upper respiratory allergies (like hay fever) and the flu. These officially approved uses extend beyond solely treating a common cold.

Q: Is Alahist CF a stimulant or a depressant?

A: The product contains two components that may have opposing effects. The antihistamine may cause drowsiness, which is a depressant effect. Conversely, the decongestant is a sympathomimetic agent that can cause sleeplessness or nervousness, which are stimulant-like effects.

Q: Are there different strengths or versions of Alahist CF available?

A: The oral tablet and liquid solutions have a fixed ratio and strength of the three active ingredients, as specified in the official product information. Different dose combinations of the three components are not listed in the standard regulatory labeling.

Q: Can Alahist CF affect sleep patterns?

A: The official regulatory labeling documents both drowsiness and sleeplessness as potential common adverse reactions. These noted side effects indicate that the product may affect an individual's sleep patterns.

Q: Does Alahist CF help with cough?

A: Yes, the product contains Dextromethorphan, which is classified as an antitussive (or cough suppressant). It is indicated for the temporary relief of cough symptoms.

Q: Can someone with diabetes take Alahist CF?

A: Official regulatory warnings state that individuals with diabetes are required by official warnings to involve consultation with a health professional before use. This warning is due to the potential for the product to affect this pre-existing health condition.

Q: Is there a risk of becoming dependent on Alahist CF?

A: The official product label includes an explicit warning that improper use or abuse of this medication may result in serious harm. This warning addresses the potential for misuse and its associated risks.

How should Alahist CF be stored and disposed of?

Storage and Disposal Instructions for Alahist CF

Alahist CF must be stored according to officially documented conditions to maintain stability and safety.

Mandatory Storage Conditions

Requirement	Specification
Temperature	Store at controlled room temperature (between 15 C and 30 C / 59 F and 86 F)
Protection	Protect from excessive heat, moisture, and light
Container	Keep in the specified tight, light-resistant container which must include a child-resistant cap

Child Safety and Disposal

To prevent accidental ingestion, the medicine must be stored out of reach of children.

Disposal of any unused or expired Alahist CF must comply with federal and local guidelines for non-controlled substances. The official guidance recommends utilizing a drug take-back program or following proper household disposal procedures if a take-back program is unavailable.

Alahist CF